The adverse consequences of early-life sleep deprivation on mental health are well recognized, yet many aspects remain unknown, therefore, animal studies can offer useful insights. Male Sprague-Dawley rats at postnatal day (PND) 19 were subjected to sleep deprivation (SD) for 14 days (6-8 hours/day). Control (CON) rats were gently handled. Behavior tests were done on PND33, PND60 and PND90. SD rats exhibited anxiety-like behavior at PND33 and PND60, when compared to CON rats. Depression-like behavior was observed at PND90. Evaluation of oxidative stress and inflammatory markers revealed interesting results. Plasma 8-isoprostane and antioxidant defense enzymes; hemeoxygenase-1, superoxide dismutase, glutathione peroxidase in the prefrontal cortex (PFC), were upregulated in SD rats at PND33 but not at PND90. PFC interleukin-6 protein expression was elevated at PND33 and PND90. PFC mitogen activated protein kinase phosphatase-1 (MKP-1) and p-38 protein expression were upregulated at PND90. PFC expression of glutamate receptor subunits, post synaptic density protein (PSD-95), calcium/calmodulin-dependent protein kinase (CaMKII), and extracellular signal-regulated kinase (ERK1/2), were significantly reduced in SD rats at PND33 and PND90. PFC brain derived neurotrophic factor (BDNF) and cAMP response element binding protein (CREB) were reduced in SD rats at PND90. Our postulation is that SD by increasing PFC oxido-inflammation, negatively affects glutamate receptor subunits and PSD95 expression, which disrupts synapse formation and maturation, potentially causing anxiety-like behavior at PND33. Oxido-inflammation further results in MKP-1 and CaMKII-mediated blockade of ERK1/2 activation, which inhibits CREB dependent BDNF expression. This most likely disrupts neuronal circuit development, leading to depression-like behavior at PND90.
Pubmed ID: 30826520 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets NMDAR2B antibody
View all literature mentionsThis monoclonal targets p38
View all literature mentionsThis polyclonal targets Rat IL-6
View all literature mentionsThis polyclonal targets p38 (phospho Y182)
View all literature mentionsThis monoclonal targets Rat CaMKII, phospho (Thr286)
View all literature mentionsThis polyclonal targets CaMKII (M-176)
View all literature mentionsThis monoclonal targets beta-actin
View all literature mentionsThis unknown targets MKP-1
View all literature mentionsThis monoclonal targets PSD-95
View all literature mentionsThis monoclonal targets AMPA Receptor 1
View all literature mentionsThis monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb
View all literature mentionsThis monoclonal targets p44/42 MAPK (Erk1/2)
View all literature mentionsThis monoclonal targets JNK1 + JNK2 + JNK3(phospho T183+T183+T221) (phospho T183 + T183 + T221) antibody [EPR5693]
View all literature mentionsThis monoclonal targets p38
View all literature mentionsThis polyclonal targets Rat IL-6
View all literature mentionsThis polyclonal targets p38 (phospho Y182)
View all literature mentionsThis monoclonal targets Rat CaMKII, phospho (Thr286)
View all literature mentionsThis polyclonal targets NMDAR2B antibody
View all literature mentions